TY - JOUR
T1 - Surveillance for control of antimicrobial resistance
AU - EPI-Net COMBACTE-MAGNET Group
AU - Tacconelli, Evelina
AU - Sifakis, Frangiscos
AU - Harbarth, Stephan
AU - Schrijver, Remco
AU - van Mourik, Maaike
AU - Voss, Andreas
AU - Sharland, Mike
AU - Rajendran, Nithya Babu
AU - Rodríguez-Baño, Jesús
AU - Bielicki, Julia
AU - de Kraker, Marlieke
AU - Gandra, Sumanth
AU - Gastmeier, Petra
AU - Gilchrist, Kim
AU - Gikas, Achilleas
AU - Gladstone, Beryl Primrose
AU - Goossens, Herman
AU - Jafri, Hasan
AU - Kahlmeter, Gunnar
AU - Leus, Frank
AU - Luxemburger, Christine
AU - Malhotra-Kumar, Surbhi
AU - Marasca, Giuseppe
AU - McCarthy, Michael
AU - Navarro, María Dolores
AU - Nuñez-Nuñez, María
AU - Oualim, Abdel
AU - Price, Jessica
AU - Robert, Jérôme
AU - Sommer, Harriet
AU - von Cube, Maja
AU - Vuong, Cuong
AU - Wiegand, Irith
AU - Witschi, Anne Therese
AU - Wolkewitz, Martin
N1 - Funding Information:
This Personal View is based on the discussion during the first annual meeting of the EPI-Net project in Tübingen in December, 2015. We thank Sergey Romualdovich Eremin (WHO, Geneva, Switzerland) and Nicola Thompson (Centers for Disease Control and Prevention, Atlanta, GA, USA) for the active participation and contribution to the meeting. We thank the Innovative Medicines Initiative Joint Undertaking for supporting the EPI-Net COMBACTE-MAGNET project (grant agreement number 115737), resources of which include financial contribution from the European Union Seventh Framework Programme (FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations companies in-kind contribution. We thank the European Society of Infectious Diseases and Clinical Microbiology and the European Committee on Infection Control for suggesting experts in epidemiology. We thank the following experts, Lisbeth Kyndi Bergen, Lubos Drgona, Vincent Jarlier, Elisabeth Presterl, Mario Poljak, and Oana Sandulescu, for their suggestions. We are grateful to the following surveillance experts for providing protocols and data information: Rossella Buttazzi (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Fortunato D'Ancona (Istituto Superiore di Sanità, Italy), Carlo Gagliotti (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Jari Jalava (National Institute for Health and Welfare, Finland), Stefan Kuster (SWISSNOSO, Switzerland), Ines Noll (Robert Koch Institute, Germany), Christiane Petignant (Prevention and control of nosocomial infections, [HPCI], Switzerland), Alberto Ricciardi (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Gunnar Skov Simonsen (Norwegian surveillance system for antimicrobial resistance, Norway), and Walter Zingg (University of Geneva Hospitals, Switzerland). We also thank Anne McDonough, a professional medical writer, for providing medical writing services.
Funding Information:
FS is an employee of AstraZeneca Pharmaceuticals LP. SH reports grants from IMI Brussels and Pfizer during the study and personal fees from DNA Electronics, Bayer, and GlaxoSmithKline outside the submitted work. MS reports grants from GlaxoSmithKline, Pfizer, and Cubist outside the submitted work. JR-B reports grants and personal fees from AstraZeneca and personal fees from Merck, InfectoPharm, Achaogen, and Basilea outside the submitted work. All other authors declare no competing interests.
Funding Information:
Acknowledgments This Personal View is based on the discussion during the first annual meeting of the EPI-Net project in T?bingen in December, 2015. We thank Sergey Romualdovich Eremin (WHO, Geneva, Switzerland) and Nicola Thompson (Centers for Disease Control and Prevention, Atlanta, GA, USA) for the active participation and contribution to the meeting. We thank the Innovative Medicines Initiative Joint Undertaking for supporting the EPI-Net COMBACTE-MAGNET project (grant agreement number 115737), resources of which include financial contribution from the European Union Seventh Framework Programme (FP7/2007?2013) and European Federation of Pharmaceutical Industries and Associations companies in-kind contribution. We thank the European Society of Infectious Diseases and Clinical Microbiology and the European Committee on Infection Control for suggesting experts in epidemiology. We thank the following experts, Lisbeth Kyndi Bergen, Lubos Drgona, Vincent Jarlier, Elisabeth Presterl, Mario Poljak, and Oana Sandulescu, for their suggestions. We are grateful to the following surveillance experts for providing protocols and data information: Rossella Buttazzi (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Fortunato D'Ancona (Istituto Superiore di Sanit? Italy), Carlo Gagliotti (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Jari Jalava (National Institute for Health and Welfare, Finland), Stefan Kuster (SWISSNOSO, Switzerland), Ines Noll (Robert Koch Institute, Germany), Christiane Petignant (Prevention and control of nosocomial infections, [HPCI], Switzerland), Alberto Ricciardi (Agenzia sanitaria e sociale regionale Emilia Romagna, Italy), Gunnar Skov Simonsen (Norwegian surveillance system for antimicrobial resistance, Norway), and Walter Zingg (University of Geneva Hospitals, Switzerland). We also thank Anne McDonough, a professional medical writer, for providing medical writing services.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/3
Y1 - 2018/3
N2 - Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data. Most incidence and prevalence data cannot be linked with relevant epidemiological, clinical, or outcome data. Genetic typing, to establish whether trends of antimicrobial resistance are caused by spread of resistant strains or by transfer of resistance determinants among different strains and species, is not routinely done. Furthermore, laboratory-based surveillance using only clinical samples is not likely to be useful as an early warning system for emerging pathogens and resistance mechanisms. Insufficient coordination of surveillance systems of human antimicrobial resistance with animal surveillance systems is even more concerning. Because results from food surveillance are considered commercially sensitive, they are rarely released publicly by regulators. Inaccurate or incomplete surveillance data delay a translational approach to the threat of antimicrobial resistance and inhibit the identification of relevant target microorganisms and populations for research and the revitalisation of dormant drug-discovery programmes. High-quality, comprehensive, and real-time surveillance data are essential to reduce the burden of antimicrobial resistance. Improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistance.
AB - Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions, infection control policies, and antimicrobial development. In Europe, although the European Antimicrobial Resistance Surveillance Network provides annual reports on monitored resistant bacteria, national surveillance efforts are still fragmented and heterogeneous, and have substantial structural problems and issues with laboratory data. Most incidence and prevalence data cannot be linked with relevant epidemiological, clinical, or outcome data. Genetic typing, to establish whether trends of antimicrobial resistance are caused by spread of resistant strains or by transfer of resistance determinants among different strains and species, is not routinely done. Furthermore, laboratory-based surveillance using only clinical samples is not likely to be useful as an early warning system for emerging pathogens and resistance mechanisms. Insufficient coordination of surveillance systems of human antimicrobial resistance with animal surveillance systems is even more concerning. Because results from food surveillance are considered commercially sensitive, they are rarely released publicly by regulators. Inaccurate or incomplete surveillance data delay a translational approach to the threat of antimicrobial resistance and inhibit the identification of relevant target microorganisms and populations for research and the revitalisation of dormant drug-discovery programmes. High-quality, comprehensive, and real-time surveillance data are essential to reduce the burden of antimicrobial resistance. Improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistance.
UR - http://www.scopus.com/inward/record.url?scp=85032574276&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(17)30485-1
DO - 10.1016/S1473-3099(17)30485-1
M3 - Review article
C2 - 29102325
AN - SCOPUS:85032574276
SN - 1473-3099
VL - 18
SP - e99-e106
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 3
ER -